Vanguard Global Advisers »

Sab Biotherapeutics shares owned by Vanguard Global Advisers

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Vanguard Global Advisers from 13F filings

Historical chart of Vanguard Global Advisers investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Vanguard Global Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Vanguard Global Advisers

Quarter filed Position value Share count Share price at filing
2026-03-31 $45k 12k 3.83

More positions owned by Vanguard Global Advisers

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Vanguard Index Fds Total Stk Mkt (VTI)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Alphabet Cap Stk Cl C (GOOG)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Meta Platforms Cl A (META)
Tesla Motors (TSLA)
Vanguard Specialized Funds Div App Etf (VIG)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
JPMorgan Chase & Co. (JPM)

View all positions for Vanguard Global Advisers

Top funds holding Sab Biotherapeutics

Vivo Capital
Perceptive Advisors
Commodore Capital
RA Capital Management
Balyasny Asset Management
Millennium Management
Woodline Partners
Vanguard Capital Management
Sessa Capital IM
Vanguard Group
Boothbay Fund Management
Ameriprise Financial
Ensign Peak Advisors
Soleus Capital Management
Propel Bio Management

View all funds holding Sab Biotherapeutics